GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alumis Inc (NAS:ALMS) » Definitions » Notes Receivable

ALMS (Alumis) Notes Receivable : $0.00 Mil (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Alumis Notes Receivable?

Alumis's Notes Receivable for the quarter that ended in Mar. 2025 was $0.00 Mil.


Alumis Notes Receivable Historical Data

The historical data trend for Alumis's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alumis Notes Receivable Chart

Alumis Annual Data
Trend Dec22 Dec23 Dec24
Notes Receivable
- - -

Alumis Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Alumis Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Alumis Notes Receivable Related Terms

Thank you for viewing the detailed overview of Alumis's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Alumis Business Description

Traded in Other Exchanges
N/A
Address
280 East Grand Avenue, South San Francisco, CA, USA, 94080
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.